Using Surrogate Insects in Acid Bioassays for Development of New Controls for Varroa destructor (Arachnida: Varroidae).

Resistance to traditional synthetic compounds by Varroa destructor Anderson and Trueman and shortcomings of the organic acid class of acaracides commonly used in varroa management requires continual development of new controls. V. destructor, however, are difficult to obtain for use in control bioassays because they are obligate parasites that cannot be easily reared outside of a honey bee colony. We conducted bioassays using other, more easily obtainable species to find organisms that could be used as surrogates for V. destructor when testing new potential controls. We compared the toxicities of acetic acid, lactic acid, formic acid, and oxalic acid at 0.005%, 0.05%, 0.5%, 5%, and 50% (20% oxalic acid only) concentrations based on natural volatility (nonheated) for the control of two beetle species, Oryzaephilus surinamensis L. and Alphitobius diaperinus Panzer, greater wax moth larvae, Galleria mellonella L., and V. destructor. The assay results were consistent across all species with formic acid and acetic acid showing 100% mortality of all four test species at 50% concentration. The assays also provided insight into the method of application (vaporization or contact) needed to cause mortality. Our results show that other organisms can be used in place of V. destructor for initial testing of acids and possibly other chemicals for control of the ectoparasite.

Unnarmicin D, an Anti-inflammatory Cyanobacterial Metabolite with δ and µ Opioid Binding Activity Discovered via a Pipeline Approach Designed to Target Neurotherapeutics.

To combat the bottlenecks in drug discovery and development, a pipeline to identify neuropharmacological candidates using in silico, in vitro, and receptor specific assays was devised. The focus of this pipeline was to identify metabolites with the ability to reduce neuroinflammation, due to the implications that chronic neuroinflammation has in chronic pain and neurodegenerative diseases. A library of pure compounds isolated from the cyanobacterium Trichodesmium thiebautii was evaluated using this method. In silico analysis of drug likelihood and in vitro permeability analysis using the parallel artificial membrane permeability assay (PAMPA) highlighted multiple metabolites of interest from the library. Murine BV-2 microglia were used in conjunction with the Griess assay to determine if metabolites could reduce lipopolysaccharide induced neuroinflammation followed by analysis of pro-inflammatory cytokine concentrations in the supernatant of the treated cell cultures. The nontoxic metabolite unnarmicin D was further evaluated due to its moderate permeability in the PAMPA assay, promising ADME data, modulation of all cytokines tested, and prediction as an opioid receptor ligand. Molecular modeling of unnarmicin D to the µ and δ opioid receptors showed strong theoretical binding potential to the µ opioid receptor. In vitro binding assays validated this pipeline showing low micromolar binding affinity for the µ opioid receptor launching the potential for further analysis of unnarmicin D derivatives for the treatment of pain and neuroinflammation related diseases.